Curated News
By: NewsRamp Editorial Staff
May 06, 2025
HeartBeam Secures Two New U.S. Patents for Innovative Cardiac Technologies
TLDR
- With new U.S. patents, HeartBeam (NASDAQ: BEAT) strengthens its position in personalized cardiac care, setting itself apart from competitors.
- HeartBeam's new patents cover a credit card-sized, cable-free 3D ECG device and a rhythm analysis algorithm for arrhythmia detection, enhancing its innovative cardiac monitoring technology.
- HeartBeam's advancements in cardiac care technology promise to revolutionize patient care, enabling real-time monitoring and early detection of cardiac issues outside medical facilities for better health outcomes.
- HeartBeam's cable-free 3D ECG device and rhythm analysis algorithm are paving the way for convenient and efficient cardiac monitoring, shaping the future of personalized healthcare.
Impact - Why it Matters
This news is significant as it showcases HeartBeam's commitment to advancing personalized cardiac care through cutting-edge technology. The issuance of these patents strengthens the company's position in the market and paves the way for future innovations in cardiac health management. Patients and healthcare providers can look forward to more advanced and accessible cardiac monitoring solutions in the near future.
Summary
HeartBeam (NASDAQ: BEAT), a medical technology company, announced the issuance of two new U.S. patents further solidifying its intellectual property position. The patents cover a credit card-sized, cable-free 3D ECG device and a rhythm analysis algorithm. These additions bring HeartBeam's total patent count to 20 issued and 34 pending or allowed, enhancing its platform for future product developments and FDA review of its 12-lead ECG synthesis software.
Source Statement
This curated news summary relied on this press release disributed by InvestorBrandNetwork (IBN). Read the source press release here, HeartBeam Secures Two New U.S. Patents for Innovative Cardiac Technologies
